Drug Profile
TRO 40303
Alternative Names: TRO-40303Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Trophos
- Class Cholestenones; Neuroprotectants; Oximes; Secosteroids; Small molecules
- Mechanism of Action Mitochondrial permeability transition pore modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial reperfusion injury
Most Recent Events
- 17 Aug 2015 Discontinued - Phase-II for Myocardial reperfusion injury (Prevention) in France, Denmark, Norway and Sweden (IV)
- 01 Sep 2013 Trophos completes a phase II trial in Myocardial reperfusion injury (Prevention) in Denmark, France, Norway and Sweden (NCT01374321)
- 04 Aug 2011 Phase-II clinical trials in Myocardial reperfusion injury (Prevention) in Denmark (IV)